Lucentis Vs Avastin

Anti-VEGF Drugs Show Equal Efficacy; Price Vastly

 Different

http://www.medscape.com/viewarticle/765234

A British trial has shown that ranibizumab and bevacizumab are equally effective in the treatment of age-related macular degeneration (AMD).

"Dr. Chakravarthy reported that there were fewer arteriothrombotic events and heart failures with bevacizumab than with ranibizumab (odds ratio [OR], 0.23; 95% CI, 0.05 to 1.07; P =.03). "This was not observed in CATT," she noted."

Well whadayya know!!....Whats more interesting is that unlike CATT, IVAN shows that in all probability, the safety profile of both drugs are similar and not leaning towards ranibizumab as previously thought. Its early results tho, so we should wait for the entire 2 years. Big debates coming!


BTW the article quotes Prof Simon Harding from St. Pauls, at the Royal in Liverpool! alma mater!